RPG Life Sciences Ltd
NSE: RPGLIFE · Pharmaceuticals · sector
₹2,761.70NSE close 2026-10-26
Key numbers
Market cap₹4,567 cr
Price₹2,761.70
52w high / low₹3,128 / ₹1,733
P/E38.2xSector median 27.9x
P/B7.5xSector median 2.9x
Book value₹366.1
Dividend yield0.87%Sector median 0.48%
ROE21.1%Sector median 11.7%
ROCE25.8%Sector median 12.3%
OPM21.6%Sector median 14.0%
Debt / equity0.03xSector median 0.16x
EV/EBITDA27.1xSector median 18.6x
Interest cover116.3x
Current ratio3.52x
Sales growth 3y+11.3%Sector median +9.6%
Profit growth 3y+19.4%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹275 cr vs borrowings ₹20 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 116.3x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 2 of the last 5 years (FY26, FY25).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 21% of net profit in the last 12 months.
- Debtor days went from 31 (FY24) to 60 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹2,761.70 on 2026-10-26: -11.7% from the 52-week high, +59.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹3,004.90 · low ₹1,744.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| EBITDA | 19 | 49 | 135 | 35 | 50 | 31 | 34 | 43 |
| OPM % | 10.8% | 28.5% | 94.6% | 21.0% | 27.7% | 17.4% | 19.2% | 22.1% |
| Other income | 2 | 3 | 5 | 5 | 5 | 3 | 12 | 5 |
| Net profit | 4 | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS (₹) | 2.54 | 21.12 | 70.96 | 15.90 | 22.28 | 13.38 | 18.08 | 18.60 |
| Revenue YoY | +5.5% | +4.2% | +23.6% | +15.8% | ||||
| Profit YoY | +777.4% | -36.6% | -74.5% | +17.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 440 | 513 | 582 | 653 | 708 | 734 |
| EBITDA | 86 | 103 | 128 | 242 | 151 | 159 |
| Net profit | 51 | 68 | 88 | 183 | 115 | 120 |
| EPS (₹) | 31.13 | 40.90 | 53.01 | 110.80 | 18.08 | 72.34 |
| Revenue growth | +16.5% | +13.5% | +12.3% | +8.3% | +11.8% | |
| Profit growth | +31.4% | +29.6% | +109.0% | -37.1% | -34.5% | |
| Dividend / share (₹) | 7.20 | 9.60 | 12.00 | 16.00 | 20.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +11.3% | +12.7% | +11.8% |
| Net profit | +19.4% | +23.6% | -34.5% |
| EPS | -23.8% | -5.7% | – |
| Share price | – | +0.9% (2y) | +16.0% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 308 | 375 | 531 | 605 |
| Borrowings | – | 0 | 0 | 0 | 20 |
| Cash & equivalents | – | 115 | 127 | 266 | 275 |
| Total assets | – | 419 | 513 | 658 | 793 |
| Fixed assets | – | 101 | 97 | 161 | 192 |
| Capital work in progress | – | 15 | 85 | 4 | 20 |
| Investments | – | 0 | 1 | 1 | 0 |
| Receivables | – | 37 | 49 | 87 | 117 |
| Inventory | – | 95 | 101 | 93 | 124 |
| Payables | – | 65 | 71 | 79 | 97 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 65 | 91 | 94 | 78 | 56 |
| Cash from investing | -35 | -106 | -79 | -42 | 86 |
| Cash from financing | -14 | -17 | -20 | -27 | -21 |
| Capex | 24 | 33 | 69 | 36 | 65 |
| Free cash flow | 41 | 58 | 25 | 42 | -9 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 22.0% | 23.4% | 34.5% | 19.0% |
| ROCE % | – | 29.9% | 31.6% | 44.0% | 24.8% |
| Debtor days | – | 27 | 31 | 48 | 60 |
| Inventory days | – | 203 | 200 | 159 | 179 |
| Payable days | – | 138 | 140 | 135 | 141 |
| Cash conversion cycle (days) | – | 92 | 91 | 72 | 98 |
| Working capital days | – | 116 | 106 | 194 | 209 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 72.95% |
| FIIs | 0.87% |
| DIIs | 9.93% |
| of which Mutual funds | 0.04% |
| of which Insurance | 0.21% |
| Government | 0.00% |
| Public (non-institutions) | 16.25% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| Promoter group | % |
|---|---|
| Nucleus Life Trust (Mr. Harsh Vardhan Goenka is a Trustee) | 53.94% |
| Ektara Enterprises Llp | 15.57% |
| Stel Holdings Limited | 3.18% |
| Harshvardhan Goenka | 0.16% |
| Mala Goenka | 0.05% |
| Carniwal Investments Limited | 0.04% |
| RG Family Trust (Mr. Anant Vardhan Goenka is a Trustee) | 0.00% |
| Ishaan Goenka Trust (Mr. Harsh Vardhan Goenka is a Trustee) | 0.00% |
| Navya Goenka Trust (Mr. Harsh Vardhan Goenka is a Trustee) | 0.00% |
| Secura India Trust (Mr. Harsh Vardhan Goenka is a Trustee ) | 0.00% |
| AVG Family Trust (Mr. Anant Vardhan Goenka is aTrustee ) | 0.00% |
| Prism Estates Trust (Mr. Harsh Vardhan Goenka is a Trustee ) | 0.00% |
| Instant Holdings Limited | 0.00% |
| Summit Securities Limited | 0.00% |
| Chattarpati Apartments Llp | 0.00% |
| Public holders above 1% | % |
|---|---|
| Clarus Capital I | 6.56% |
| Authum Investment and Infrastructure Limited | 2.02% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.08% |
24,330 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| RPGLIFE | ₹4,567 cr | 38.2x | 7.5x | 21.1% | 25.8% | 21.6% | +11.3% | 0.87% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-09 | Dividend | Dividend - Rs 24 Per Share |
| 2025-06-27 | Dividend | Dividend - Rs 20 Per Share/ Special Dividend - Rs 4 Per Share |
| 2024-06-28 | Dividend | Dividend - Rs 16 Per Share |
| 2023-07-21 | Dividend | Dividend - Rs 12 Per Share |
| 2022-07-14 | Dividend | Dividend - Rs 9.60 Per Share |
| 2021-08-13 | Dividend | Dividend - Rs 7.20 Per Share |
| 2020-03-24 | Dividend | Interim Dividend - Rs 4 Per Share |
| 2019-07-22 | Dividend | Annual General Meeting/ Dividend - Rs 2.40 Per Share |
| 2018-07-19 | Dividend | Annual General Meeting/Dividend- Rs 2.40 Per Share |
| 2017-07-13 | Dividend | Annal General Meeting/Dividend - Rs 2.80 Per Share |
| 2016-07-19 | Other | Annual General Meeting |
| 2016-03-22 | Dividend | Interim Dividend - Rs 1.60/- Per Share |
| 2015-07-20 | Dividend | Annual General Meeting And Dividend Re.0.80 Per Share |
| 2014-09-11 | Dividend | Annual General Meeting / Dividend - Rs 1.20/- Per Share + Special Dividend - Re 0.80/- Per Share |
| 2013-07-11 | Dividend | Annual General Meeting / Dividend - Rs 1.20/- Per Share |
| 2012-07-24 | Dividend | Annual General Meeting/ Dividend Rs. 0.80 Per Share |
| 2011-07-14 | Dividend | Annual General Meeting And Dividend Rs.1.60 Per Share |
| 2010-07-15 | Dividend | Annual General Meeting And Dividend Rs.1.44 Per Share |
| 2009-07-30 | Other | Agm/Div-Rs.1.20 Per Share |
| 2008-08-11 | Dividend | Agm/Dividend - 15% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceutical: Manufacturing and marketing of pharmaceutical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | RPGLIFE |
| BSE code | 532983 |
| ISIN | INE105J01010 |
| Face value | ₹8.0 |
| Incorporated | 2007-03-27 |
| Website | www.rpglifesciences.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.